

TABLE OF CONTENTS

July 20, 2009

No. 2148

BUSINESS

- 1 Treatment with Sprycel Begun in 600 Patients: Bristol-Myers
- 2 Micombi Can Be Differentiated from Other Combination Drugs: Mr Imahori of Astellas
- 2 Higher Dosage Approved for Cravit: Daiichi Sankyo
- 2 **BUSINESS NEWS IN BRIEF**
 - JCR to Tie-up with Bio Matrix for Antibody Pharmaceuticals
 - Sciele Terminates Proposed Merger Agreement with Victory Pharma
 - Kringle Pharma Raises ¥830 Mil.
 - Takara Bio to Continue 10 More Years of Investment in Gene Therapy Business: President Omiya
 - 257 Employees Apply for Early Retirement Program: Mediceo Paltac

REGULATORY

- 4 Prasugrel Approved in the US
 - 1,800 MR System Established
 - Effient/Efient to Lift Ube Industries' Pharma Business
- 6 23 Drug Products Approved
 - Enbrel Approved for JIA as Additional Indication
 - Caduet Approved as Japan's 1st Combination of Antihypertensive and Antihyperlipidemic: Pfizer Japan
 - Avolve Approved for Prostatic Hyperplasia: GSK
 - Prograf Approved for Refractory Ulcerative Colitis: Astellas
 - Antidepressant Mirtazapine Approved: Schering-Plough, Meiji Seika
 - New Treatment Regimen Approved for Remicade: MTPC
 - Rasilez Approved for Hypertension: Novartis
 - Gonalef Approved for Infertility in Women: Merck Serono

REGULATORY NEWS IN BRIEF

- 8
 - Celgene Applies for Revlimid for MM
 - Liraglutide Obtains EU Approval for Type 2 Diabetes: Novo
 - Multaq Approved for Arrhythmia by FDA: sanofi-aventis
 - Cimzia Recommended for EU Approval for RA: UCB

GENERICIS

- 10 Anplag to Be Major Target for Generic NHI Price Listing in November
- 10 Survey on Generics of Anticancer Drugs Shows Gaps between Generic Firms and Healthcare Professionals
 - Development Presents Number of Challenges

GENERICIS NEWS IN BRIEF

- Mylan Ties Up with Indian Biotech Company for Biosimilars
- JPA Prepares Leaflet to Help Pharmacists Explain about Generics to Patients
- MED Calls For Compliance with *Ryotan Kisoku*

COMMENTARY

- 12 Hitech Drugs Open the Window to the Future: Sugio Seko

R&D

- 16 Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
- 16 ASCO 2009 Highlight Seminar by the Matson Jack Group
 - Direct Comparison Essential for Drugs for RCC
- 16 Japan Biotechnology Conference "Kicked Off by 20 Biotech Firms"

R&D NEWS IN BRIEF

- 17
 - Eisai Starts PII Trial of Dacogen in Children with AML
 - CanBas' CBP501 Enters PII for NSCLC: Takeda
 - Sutent Improves PFS for Patients with Advanced Pancreatic Islet Cell Tumors: Pfizer
 - Epadel Prevents Recurrence of Coronary Events: Large-Scale Trial
 - Epogin Meets Primary Endpoint for Chemotherapy-Induced Anemia
 - Anti-Tumor Effects of CEP Reported
 - Lantus Shows Long-Term Safety Compared to NPH
 - Alnylam Licenses RNAi Patents to Develop NTD Drugs to GSK
 - Merck to Collaborate with DNDi to Codevelop Drugs for Neglected Diseases

SELF-MEDICATION

- 20 New Class 1 OTC Drugs Get Off to Flying Start: Taisho
- 20 Sales of Class 1 OTC Drugs Down due to New Marketing System
- 21 Fuji Keizai Predicts 4% Increase in OTC Anti-Obesity Drugs in 2009

MEDICAL FACILITIES & NURSING CARE

- 21 Flat-Sum System to Be Maintained for High-Priced Drugs
- 22 Adoair Included in GL for COPD
- 22 Provide Correct Information on Medical Narcotics to Patients: Dr Konishi
- 23 Experts Petition Early Approval for Cervical Cancer Vaccines

TOPICS

- 23
 - Pfizer Offers Reduced Working-Hour Program for MRs